NVNO enVVeno Medical Corporation
USHealthcareAs of 2026-07-10 13:55
Why NVNO matters now
enVVeno Medical Corporation (NVNO) is a US stock in Healthcare. The latest InvestLog snapshot shows $11.80 with +7.27% on the session and $194.7K in market capitalization; recent performance reads 1-month -1.48% and YTD -12.28%.
The latest financial table shown here is Q1 2026, with revenue of $0.00, net income of $-3.8M, and EPS of $-233.94. Investors can compare that operating picture with valuation signals such as P/E unavailable and FCF yield -8963.8%.
The latest indexable market news headline is "enVVeno Medical Secures Transformational U.S. Patent for enVVe System, Strengthening Competitive Moat Ahead of Launch of Historic FDA Pivotal Trial" from Accesswire.
Additional event context on this page matters because analyst consensus is Hold with a median target of $—; recent insider activity includes Duhay Francis filing S-Sale. These signals are research inputs, not a recommendation.
Valuation
P/E (TTM)
—
PEG
—
P/B
0.01
P/S
0.00
EV/EBITDA
0.10
DCF Value
$3.46
FCF Yield
-8963.8%
Div Yield
0.0%
Margins & Returns
Gross Margin
0.0%
Operating Margin
0.0%
Net Margin
0.0%
ROE
-66.4%
ROA
-72.1%
ROIC
-82.2%
Financials
| Period | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $0.00 | $-3.8M | $-233.94 |
| Q4 2025 | $0.00 | $-3.7M | $-227.07 |
| FY 2025 | $0.00 | $-19.5M | $-33.06 |
| Q3 2025 | $0.00 | $-4.5M | $-281.75 |
Analyst Ratings
Consensus
Hold
Target (Consensus)
$—
Target (Median)
$—
Target Range
$— - $—
Trading Activity
Insider Trades
Related Stocks
Latest News
Company Info
Sector
Healthcare
Industry
Medical - Devices
Country
US
Exchange
—
Beta
1.09
enVVeno Medical Corporation, based in Irvine, California, is a medical device firm founded in 1999 that is currently in its clinical development phase. The company's primary objective is to pioneer advanced bioprosthetic, tissue-engineered solutions intended to significantly elevate the existing standards of care for patients suffering from venous conditions. Their flagship product is the VenoValve, a specialized replacement venous valve developed for the management of chronic venous insufficiency. This device requires an open surgical procedure for implantation, which involves making a 5-to-6-inch incision in the patient's upper thigh to facilitate placement into the femoral vein. In addition to the VenoValve, enVVeno Medical is actively developing the enVVe system. This innovative system represents a non-surgical, transcatheter approach to venous valve replacement, comprising the enVVe valve itself, a dedicated delivery mechanism, and various supplementary accessories. The company previously operated under the name Hancock Jaffe Laboratories, Inc., before officially rebranding to enVVeno Medical Corporation in October 2021.